Which has more human data?

Going by the research status on each profile (Semaglutide: FDA-approved; Tirzepatide: FDA-approved), they carry the same label, so the status alone does not separate them. Each profile's References section lists the studies, with the species and study type.

What are the half-lives?

Semaglutide: ~7 days. Tirzepatide: ~5 days. Figures are as reported in the cited studies, with the species where stated.

Are they FDA-approved?

Semaglutide: research status “FDA-approved”. FDA-approved. Semaglutide is no longer on the FDA shortage list, so 503A/503B compounding of copies is restricted. Tirzepatide: research status “FDA-approved”. FDA-approved. Removed from the FDA shortage list, so compounding of copies is restricted. See the FDA peptide regulatory tracker for sourced compounding status.

How are they administered in the research?

Semaglutide: Subcutaneous injection. Tirzepatide: Subcutaneous injection. This describes the published studies and is not a recommendation for human use.

How do their proposed mechanisms differ?

Semaglutide: In plain terms: It copies the gut hormone GLP-1, which is described as reducing appetite and slowing how fast the stomach empties. Proposed mechanism (GLP-1 receptor agonist pharmacology): GLP-1 receptor activation is described as reducing appetite and slowing gastric emptying. Its effect on body weight comes from clinical trials: in the STEP 1 phase 3 RCT in adults with overweight or obesity, once-weekly semaglutide 2.4 mg with lifestyle intervention produced a mean weight change of -14.9% at 68 weeks vs -2.4% with placebo (Wilding 2021). Tirzepatide: In plain terms: It acts on two gut-hormone receptors (GIP and GLP-1) and led to weight loss in a clinical trial. Dual GIP and GLP-1 receptor agonist, developed to test whether GIP's metabolic action adds to GLP-1 receptor agonism (Coskun 2018). Its effect on body weight comes from clinical trials: in the SURMOUNT-1 phase 3 RCT (n=2539), mean weight change at 72 weeks was -15.0% to -20.9% with 5-15 mg weekly vs -3.1% with placebo (Jastreboff 2022). These are mechanisms proposed in the cited research, at the research stage listed for each compound.

Semaglutide vs Tirzepatide: Research Comparison

Built from the Semaglutide, Tirzepatide research profiles · Profiles last updated October 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team

TL;DR

This page compares Semaglutide and Tirzepatide using only their research-profile data. Semaglutide (research stage: FDA-approved; half-life: About 7 days). It copies the gut hormone GLP-1, which is described as reducing appetite and slowing how fast the stomach empties. Tirzepatide (research stage: FDA-approved; half-life: About 5 days). It acts on two gut-hormone receptors (GIP and GLP-1) and led to weight loss in a clinical trial. Educational summary, not medical advice.

Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies

Educational summary. Everything below is taken from each compound's research profile and describes what was reported in the cited studies — not a promise of results, a dose recommendation, or an endorsement for human use. Not medical advice. Full disclaimer.

Side-by-side comparison

	Semaglutide	Tirzepatide
Category	Metabolic	Metabolic
Research status	FDA-approved	FDA-approved
Regulatory note (as of Sept 2026)	FDA-approved. Semaglutide is no longer on the FDA shortage list, so 503A/503B compounding of copies is restricted. Regulatory tracker →	FDA-approved. Removed from the FDA shortage list, so compounding of copies is restricted. Regulatory tracker →
Half-life	~7 days	~5 days
Administration route	Subcutaneous injection	Subcutaneous injection
Dosing used in published research (not a recommendation)	Humans: 2.4 mg s.c. once weekly for 68 weeks, n=1961 (STEP 1, Wilding 2021). 0.5-1.0 mg s.c. weekly in healthy Japanese and Caucasian men (2018 PK trial).	Humans: 5, 10 or 15 mg s.c. once weekly for 72 weeks after a 20-week escalation, n=2539 (SURMOUNT-1, Jastreboff 2022). Phase 1: 0.25-15 mg (Coskun 2018).
Community-reported protocol (not from clinical studies)	Community-reported0.25–2.4 mg weekly, subcutaneous injection	Community-reported2.5–15 mg weekly, subcutaneous injection
How it works (as summarized from the cited research)	In plain terms: It copies the gut hormone GLP-1, which is described as reducing appetite and slowing how fast the stomach empties. Proposed mechanism (GLP-1 receptor agonist pharmacology): GLP-1 receptor activation is described as reducing appetite and slowing gastric emptying. Its effect on body weight comes from clinical trials: in the STEP 1 phase 3 RCT in adults with overweight or obesity, once-weekly semaglutide 2.4 mg with lifestyle intervention produced a mean weight change of -14.9% at 68 weeks vs -2.4% with placebo (Wilding 2021).	In plain terms: It acts on two gut-hormone receptors (GIP and GLP-1) and led to weight loss in a clinical trial. Dual GIP and GLP-1 receptor agonist, developed to test whether GIP's metabolic action adds to GLP-1 receptor agonism (Coskun 2018). Its effect on body weight comes from clinical trials: in the SURMOUNT-1 phase 3 RCT (n=2539), mean weight change at 72 weeks was -15.0% to -20.9% with 5-15 mg weekly vs -3.1% with placebo (Jastreboff 2022).
Effects reported in research (study subjects as stated)	ClinicalIn the STEP 1 randomized controlled trial (n=1961 adults with overweight or obesity): once-weekly semaglutide was studied for weight management (Wilding 2021) ClinicalIn clinical use (FDA label): adjunct to diet and exercise to improve glycemic control in type 2 diabetes (Ozempic)	ClinicalMean 15-21% weight reduction at 72 weeks vs 3.1% with placebo (SURMOUNT-1 Phase 3 trial) ClinicalIn clinical use (FDA label): adjunct to diet and exercise to improve glycemic control in type 2 diabetes (Mounjaro)
Potential side effects	Gallbladder events (cholelithiasis) Lab / animalThyroid C-cell tumor boxed warning (rodent data)	ClinicalGI adverse events led to discontinuation in 4.3-7.1% vs 2.6% on placebo (SURMOUNT-1) Lab / animalThyroid C-cell tumor boxed warning (rodent data)
Profile description	GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. Brand names include Ozempic and Wegovy. Semaglutide is a prescription-only medication and must be obtained and used under the supervision of a licensed healthcare provider.	Dual GIP/GLP-1 receptor agonist. In the SURMOUNT-1 Phase 3 trial, mean weight reduction was 15-21% at 72 weeks vs 3.1% with placebo. Brand names include Mounjaro and Zepbound. Tirzepatide is a prescription-only medication and must be obtained and used under the supervision of a licensed healthcare provider.
References cited on the profile	2	2

Key differences in the published research

Research status: the same on every profile (FDA-approved).
FDA approval: every compound compared here carries an “FDA-approved” research status.
Category: the same on every profile (Metabolic).
Reported half-life: Semaglutide — ~7 days; Tirzepatide — ~5 days.
Administration route in the literature: the same on every profile (Subcutaneous injection).
Evidence cited: Semaglutide’s profile lists 2 references; Tirzepatide’s profile lists 2 references.

Regulatory status

Semaglutide: On the FDA peptide regulatory tracker: FDA-approved drug. Details →
Tirzepatide: On the FDA peptide regulatory tracker: FDA-approved drug. Details →

For the sourced, dated status of every peptide in FDA's 2026 compounding actions, see the FDA peptide regulatory tracker.

Frequently Asked Questions

Which has more human data?: Going by the research status on each profile (Semaglutide: FDA-approved; Tirzepatide: FDA-approved), they carry the same label, so the status alone does not separate them. Each profile's References section lists the studies, with the species and study type.
What are the half-lives?: Semaglutide: ~7 days. Tirzepatide: ~5 days. Figures are as reported in the cited studies, with the species where stated.
Are they FDA-approved?: Semaglutide: research status “FDA-approved”. FDA-approved. Semaglutide is no longer on the FDA shortage list, so 503A/503B compounding of copies is restricted. Tirzepatide: research status “FDA-approved”. FDA-approved. Removed from the FDA shortage list, so compounding of copies is restricted. See the FDA peptide regulatory tracker for sourced compounding status.
How are they administered in the research?: Semaglutide: Subcutaneous injection. Tirzepatide: Subcutaneous injection. This describes the published studies and is not a recommendation for human use.
How do their proposed mechanisms differ?: Semaglutide: In plain terms: It copies the gut hormone GLP-1, which is described as reducing appetite and slowing how fast the stomach empties. Proposed mechanism (GLP-1 receptor agonist pharmacology): GLP-1 receptor activation is described as reducing appetite and slowing gastric emptying. Its effect on body weight comes from clinical trials: in the STEP 1 phase 3 RCT in adults with overweight or obesity, once-weekly semaglutide 2.4 mg with lifestyle intervention produced a mean weight change of -14.9% at 68 weeks vs -2.4% with placebo (Wilding 2021). Tirzepatide: In plain terms: It acts on two gut-hormone receptors (GIP and GLP-1) and led to weight loss in a clinical trial. Dual GIP and GLP-1 receptor agonist, developed to test whether GIP's metabolic action adds to GLP-1 receptor agonism (Coskun 2018). Its effect on body weight comes from clinical trials: in the SURMOUNT-1 phase 3 RCT (n=2539), mean weight change at 72 weeks was -15.0% to -20.9% with 5-15 mg weekly vs -3.1% with placebo (Jastreboff 2022). These are mechanisms proposed in the cited research, at the research stage listed for each compound.

References

Semaglutide

Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I et al. The New England journal of medicine. 2021. PMID: 33567185.
Study type: RCT n=1961 (STEP 1).
DOI: 10.1056/NEJMoa2032183 · PubMed
A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects
Ikushima I, Jensen L, Flint A, Nishida T, Zacho J, Irie S. Advances in therapy. 2018. PMID: 29536338.
Study type: Human PK RCT n=44.
DOI: 10.1007/s12325-018-0677-1 · PubMed

Tirzepatide

Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B et al. The New England journal of medicine. 2022. PMID: 35658024.
Study type: Phase 3 RCT n=2539 (SURMOUNT-1).
DOI: 10.1056/NEJMoa2206038 · PubMed
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB et al. Molecular metabolism. 2018. PMID: 30473097.
Study type: Phase 1 RCT n=142.
DOI: 10.1016/j.molmet.2018.09.009 · PubMed

Read the full profiles

From Our Affiliated Clinic

Considering physician-supervised GLP-1 therapy?

1836 Wellness — operated by the same company as The Peptide Dispatch — offers physician-supervised protocols, 76-marker blood panels, and bio-age scoring.

Visit 1836 Wellness →

Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.

Educational content — not medical advice. Effects described are drawn from cited research in study subjects.

← Compare Peptides Peptide Database Regulatory Tracker Home